Patents Assigned to Biosite Diagnostics
  • Patent number: 5679526
    Abstract: This invention is directed to a ligand-receptor assay for determining the presence of at least one target ligand, capable of competing with a ligand analogue conjugate for binding sites available on a ligand receptor, said ligand analogue conjugate comprising at least one ligand analogue coupled to a colloidal gold particle, in a fluid sample suspected of containing said target ligand comprising the steps of:a. contacting said fluid sample with said ligand analogue conjugate and said ligand receptor to form a homogeneous reaction mixture, the relative amounts of said ligand analogue conjugate and said ligand receptor being selected such that in the absence of said target ligand and subsequent to substantially equilibrium binding in said reaction mixture, substantially all of said ligand analogue conjugate is bound to said ligand receptor such that no unbound ligand analogue conjugate is detected as a result of the assay method;b.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: October 21, 1997
    Assignee: Biosite Diagnostics Incorporated
    Inventors: Kenneth F. Buechler, Gunars E. Valkirs, Richard R. Anderson
  • Patent number: 5610283
    Abstract: The present invention is directed to novel opiate derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the opiates and opiate metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: March 11, 1997
    Assignee: Biosite Diagnostics Incorporated
    Inventor: Kenneth F. Buechler
  • Patent number: 5525524
    Abstract: Assay for detecting the amount or presence of target ligand in a sample. The assay includes a ligand analogue conjugate having a linkage site and a binding site, a ligand receptor, and a sample. The assay includes the steps of providing at least one crosstalk inhibitor. This inhibitor, under assay conditions, competes with the linkage site of the ligand analogue conjugate for binding to the ligand receptor, and does not compete with the binding site of the ligand analogue conjugate for binding to the ligand receptor. In the invention, the assay is performed for the target ligand in the presence of a sufficient amount of the crosstalk inhibitor to reduce the amount of binding of the linkage site of the ligand analogue conjugate to the ligand receptor. The invention also features a method for identifying crosstalk inhibitors, and the crosstalk inhibitors themselves.
    Type: Grant
    Filed: August 3, 1993
    Date of Patent: June 11, 1996
    Assignee: Biosite Diagnostics, Inc.
    Inventors: Kenneth F. Buechler, Richard R. Anderson, Theodore T. Lee, Gunars E. Valkirs
  • Patent number: 5480792
    Abstract: Methods and test devices for detecting the presence or amount of target ligand in non-competitive sandwich ligand-receptor assay processes. Antibodies which bind to the complex of ligand receptor and target ligand but do not bind significantly to the ligand receptor and which bind the target ligand with substantially less affinity than the complex are taught and their uses described. These assays can be used to eliminate the "hook" effect in non-competitive sandwich assays. Furthermore, the antibodies are selected and assay methods described so that, as a result of the assay process, no detectable response is observed due to the binding of antibody and ligand receptor in the absence of target ligand.
    Type: Grant
    Filed: June 1, 1993
    Date of Patent: January 2, 1996
    Assignee: Biosite Diagnostics, Inc.
    Inventors: Kenneth F. Buechler, Gunars E. Valkirs
  • Patent number: 5470997
    Abstract: The present invention is directed to novel amphetamine derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to amphetamine and amphetamine metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
    Type: Grant
    Filed: April 6, 1992
    Date of Patent: November 28, 1995
    Assignee: Biosite Diagnostics Incorporated
    Inventors: Kenneth F. Buechler, Joseph B. Noar, Si S. Moi
  • Patent number: 5458852
    Abstract: The assay devices, assay systems and device components of this invention comprise at least two opposing surfaces disposed a capillary distance apart, at least one of which is capable of immobilizing at least one target ligand or a conjugate in an amount related to the presence or amount of target ligand in the sample from a fluid sample in a zone for controlled fluid movement to, through or away the zone. The inventive device components may be incorporated into conventional assay devices with membranes or may be used in the inventive membrane-less devices herein described and claimed. These components include flow control elements, measurement elements, time gates, elements for the elimination of pipetting steps, and generally, elements for the controlled flow, timing, delivery, incubation, separation, washing and other steps of the assay process.
    Type: Grant
    Filed: May 21, 1992
    Date of Patent: October 17, 1995
    Assignee: Biosite Diagnostics, Inc.
    Inventor: Kenneth F. Buechler
  • Patent number: 5414085
    Abstract: The present invention is directed to novel barbiturate derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the barbiturate metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
    Type: Grant
    Filed: April 6, 1992
    Date of Patent: May 9, 1995
    Assignee: Biosite Diagnostics, Inc.
    Inventor: Kenneth F. Buechler
  • Patent number: 5331109
    Abstract: The present invention is directed to novel PCP derivatives which are synthesized for the covalent attachment to antigens or receptors (proteins or polypeptides) for the preparation of antibodies or receptors to PCP and PCP analogue metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
    Type: Grant
    Filed: April 6, 1992
    Date of Patent: July 19, 1994
    Assignee: Biosite Diagnostics Incorporated
    Inventor: Kenneth F. Buechler
  • Patent number: 5302703
    Abstract: The present invention is directed to novel THC derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the THC metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
    Type: Grant
    Filed: March 17, 1993
    Date of Patent: April 12, 1994
    Assignee: Biosite Diagnostics Incorporated
    Inventors: Kenneth F. Buechler, Si S. Moi
  • Patent number: 5302715
    Abstract: The present invention is directed to novel benzodiazepine derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the benzodiazepine metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
    Type: Grant
    Filed: April 6, 1992
    Date of Patent: April 12, 1994
    Assignee: Biosite Diagnostics, Inc.
    Inventors: Kenneth F. Buechler, Joseph B. Noar
  • Patent number: 5237057
    Abstract: The present invention is directed to novel THC derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the THC metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
    Type: Grant
    Filed: April 6, 1992
    Date of Patent: August 17, 1993
    Assignee: Biosite Diagnostics, Inc.
    Inventors: Kenneth F. Buechler, Si S. Moi
  • Patent number: 5233042
    Abstract: Compounds are provided for the preparation of reagents, including labels which can be used in immunoassays of cocaine and cocaine metabolites. The compounds are derivatives of cocaine which are conjugated to antigenic proteins or polypeptides for the formation of antibodies for use in immunoassays. The compounds also may be conjugated to labels for use in immunoassays.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: August 3, 1993
    Assignee: Biosite Diagnostics, Inc.
    Inventor: Kenneth F. Buechler
  • Patent number: 5143852
    Abstract: Means for the detection of free ligand analogue conjugate in fluids from competitive ligand-receptor assay processes. Ligand analogue antibodies that bind the ligand analogue conjugate with substantially greater affinity than their affinity for target ligand are selected and used in competitive ligand-receptor assay processes to bind the free fraction of the ligand analogue conjugate. This means permits the detection of the free fraction of ligand analogue conjugate even in the presence of substantially higher concentrations of free target ligand. For the purposes of the present invention, ligand analogue antibodies are antibodies that exhibit at least 100.times.greater affinity for the ligand analogue conjugate compared to their affinity for the target ligand.
    Type: Grant
    Filed: September 14, 1990
    Date of Patent: September 1, 1992
    Assignee: Biosite Diagnostics, Inc.
    Inventors: Gunars E. Valkirs, Kenneth F. Buechler
  • Patent number: 5089391
    Abstract: This invention is directed to a ligand-receptor assay for determining the presence or amount of at least one target ligand, capable of competing with a ligand analogue conjugate for binding sites available on a ligand receptor, said ligand analogue conjugate comprising at least one ligand analogue coupled to a signal development element capable of emitting a detectable signal, in a fluid sample suspected of containing said target ligand, comprising the steps of:a. contacting said fluid sample with ligand analogue conjugate and ligand receptor to form a reaction mixture, the relative amounts of ligand analogue conjugate and ligand receptor being such that in the absence of target ligand, and subsequent to substantially equilibrium binding, substantially all of the ligand analogue conjugate is bound to ligand receptor;b. detecting the unbound ligand analogue conjugate;c. relating the detectable signal to the presence or amount of target ligand in the fluid sample.
    Type: Grant
    Filed: January 10, 1990
    Date of Patent: February 18, 1992
    Assignee: Biosite Diagnostics, Inc.
    Inventors: Kenneth F. Buechler, Gunars E. Valkirs, Richard R. Anderson
  • Patent number: 5028535
    Abstract: This invention is directed to a ligand-receptor assay for determining the presence or amount of at least one target ligand, capable of competing with a ligand analogue conjugate for binding sites available on a ligand receptor, said ligand analogue conjugate comprising at least one ligand analogue coupled to a signal development element capable of emitting a detectable signal, in a fluid sample suspected of containing said target ligand, comprising the steps of:a. contacting said fluid sample with ligand analogue conjugate and ligand receptor to form a reaction mixture, the relative amounts of ligand analogue conjugate and ligand receptor being such that in the absence of target ligand, and subsequent to substantially equilibrium binding, substantially all of the ligand analogue conjugate is bound to ligand receptor;b. detecting the unbound ligand analogue conjugate;c. relating the detectable signal to the presence or amount of target ligand in the fluid sample.
    Type: Grant
    Filed: January 10, 1989
    Date of Patent: July 2, 1991
    Assignee: Biosite Diagnostics, Inc.
    Inventors: Kenneth F. Buechler, Gunars E. Valkirs, Richard R. Anderson